Background
Nuclear hormone receptors (NHRs) are a family of proteins encoded by 53 unique genes that generate changes in RNA transcription in response to external ligands [
1]. The protein structure of NHRs consists of two domains – a ligand binding domain and a DNA-binding domain. Most NHRs have no known ligand and are not well characterized at a functional level. However, a small subset of NHRs – such as the estrogen (ER), progesterone (PR), androgen (AR), and thyroid receptors – and their ligands are well-studied because of their critical roles in reproductive physiology and development. For example, estrogen and progesterone mimetics are commonly used to regulate the uterine menstrual cycle as part of hormonal contraception regimens [
2]. In addition, women who have severe hypothyroidism are more likely to have uterine menstrual disturbances [
3,
4]. The NHRs thus play critical roles in both normal uterine physiology as well as uterine cancers.
Endometrial cancer arises from the inner lining of the uterus. The incidence of endometrial cancer in U.S. Caucasian women increased by 1–2% per year, on average, over the 10-year period from 2003 to 2012 [
5,
6]. The loss of expression of NHRs, particularly of ER and PR, has been associated with poor clinical outcomes in endometrial carcinoma [
7]. NHR expression may thus serve as a prognostic tool that can identify, at an early stage, subgroups of patients who are likely to develop an aggressive cancer in the future. ER and PR expression are also tightly correlated with the first of two classic histologic subtypes of endometrial cancer, type I and type II [
8], which are used in combination with clinical features to risk-stratify patients and tailor treatment regimens. The identification of novel subgroups of endometrial cancer patients based on nuclear hormone receptor expression could aid in the development of new prognostic tools and therapeutic strategies to treat endometrial cancer.
Previous studies have highlighted the importance of nuclear receptor hormone expression in endometrial cancer. For example, unsupervised clustering of gene expression data from hundreds of patient tumors in The Cancer Genome Atlas (TCGA) uncovered a “hormonal” subtype of endometrial cancer associated with increased ER and PR expression and a favorable clinical prognosis [
9]. The hormone receptor-positive subgroup was associated with phosphatase and tensin homolog (
PTEN) mutations and a few tumor protein p53 (
TP53) mutations and copy number alterations. These findings were consistent with previous associative studies that found links between the loss of ER or PR expression and poor clinical outcomes in endometrial cancer [
10‐
12]. However, a targeted characterization of the role of the broader nuclear hormone receptor family in predicting clinical outcomes remains unaddressed. In part, this is because a computational framework for reliably detecting subgroups of patients who lose expression of NHRs relative to normal tissue has not yet been developed. The availability of a method for reliably subgrouping endometrial cancers patients based on their NHR status would facilitate the identification of novel biomarkers of disease progression.
Here, we develop a new computational approach termed
receptLoss for identifying nuclear hormone receptors that lose expression in a subset of endometrial carcinomas relative to adjacent normal tissue [
13]. Previously established associations between estrogen receptor (
ESR1) and progesterone receptor (
PGR) loss of expression and poor survival are confirmed by applying
receptLoss to mRNA expression data from endometrial tumors in TCGA [
14,
15]. In addition, a novel association between thyroid receptor beta (
THRB) expression loss and improved 5-year survival in endometrial carcinoma is described. Finally, we show that
THRB expression loss occurs independently of
ESR1 and
PGR expression. In sum, these results describe a novel subgroup of endometrial cancers with differential survival based on
THRB expression. In addition,
receptLoss is a freely-available bioinformatics tool that can be utilized to identify subgroups of tumors that lose expression relative to normal tissue for any tumor type.
Discussion
The loss of estrogen, progesterone, and androgen receptor expression has been used to define clinically-relevant subtypes of endometrial tumors that are associated with poor outcomes [
23,
31,
37]. Here, a novel open-source tool termed
receptLoss was developed to identify subsets of patient tumors that have lost NHR expression relative to normal tissue.
ReceptLoss relies solely on gene expression data from tumor and normal tissue and does not incorporate prior knowledge of whether an NHR has a known prognostic role.
ReceptLoss therefore represents a novel, data-driven approach free of literature bias to identify new NHR-based biomarkers in cancer. Prior data-driven and literature-free approaches such as
oncomix (also developed in our group) have also been developed to identify novel candidate biomarkers and driver genes in cancer based on non-standard gene expression distributions [
38]. These mRNA-centric approaches provide a systematic approach for expanding the list of promising cancer biomarkers whose effects are mainly driven by changes in mRNA expression rather than by DNA mutation.
In the context of endometrial cancer,
receptLoss correctly identified several well-known nuclear hormone receptors, including
ESR1,
AR, and
PGR, that have previously been shown to have low expression in a subset of endometrial carcinomas [
10,
23]. This work expands the pool of NHRs as oncologic biomarkers by showing that three previously undescribed NHRs lose expression in a subset of endometrial tumors –
THRB, PPARG, and
NR4A1. The previously undescribed connection between these three NHRs and endometrial cancer will be described in turn.
Thyroid receptor beta (TRβ, encoded by
THRB) is an NHR that modulates growth signaling in both normal human development and cancerous tissue [
39]. To date, the expression of
THRB in endometrial carcinoma has not been characterized. We report, for the first time, that
THRB expression is lost in a subset of endometrial carcinomas and is associated with poorer 5-year survival. Previous studies have examined the relationship between thyroid hormone receptor expression and outcomes in other cancers. For example, in breast cancer, TRβ protein positivity was associated with better 5-year survival in
BRCA1 mutated cancers but not in sporadic breast cancers [
40].
The mechanisms by which
THRB expression is lost in endometrial cancer remain under investigation. Here, we discuss two plausible mechanisms identified from this study. First, studies in papillary thyroid carcinoma [
35] and renal cell carcinoma [
36] have both shown that microRNAs downregulate expression of
THRB, and that other molecular modifications, such as promoter methylation, are less involved in regulating
THRB expression. We report for the first time that increased expression of miR146-a, a microRNA that has been experimentally shown to bind and degrade
THRB mRNA in papillary thyroid carcinoma [
35], is associated with the loss of
THRB expression in endometrial carcinomas. In addition, a previous study found a single nucleotide polymorphism (rs2910164 G > C) within the pre-miRNA of miR146-a that decreases the risk for endometrial and ovarian cancer [
41]. However, further studies are warranted to conclusively determine the relationship between miR146-a and
THRB expression in endometrial cancer. Second, a relationship between microsatellite instability and loss of
THRB expression in endometrial cancer is identified in this study for the first time. A prior study showed that mRNA expression of thyroid receptor alpha (
THRA) is correlated with changes in intronic microsatellite length within the
THRA locus [
42]. The
THRB locus also contains several microsatellite regions, which raises the question of whether
THRB expression could be similarly altered by changes in intragenic microsatellite length and stability.
Intriguingly, the fact that loss of
THRB expression is correlated with better patient survival is contrary to that of other hormone receptors, whose increased expression is often associated with better clinical outcomes. One possible explanation for this paradoxical observation is that
THRB expression may accelerate endometrial carcinogenesis. The initial discovery of
THRB as erbA2, an avian retroviral oncogene with a human homolog, supports this hypothesis [
43,
44]. Furthermore,
THRB is not co-expressed with other NHRs (Fig.
7a), suggesting that
THRB expression could be used to categorize patients into novel clinically-relevant subgroups, much like the molecular expression profiling (e.g. OncotypeDx) used in breast tumors to determine whether a patient’s tumor is likely to recur [
45]. These subgroups, in turn, could be useful for precision oncology efforts that modulate thyroid receptor signaling or function for the treatment of endometrial cancer. Indeed, therapeutic modulation of TRβ activity has been proposed as a therapeutic strategy to treat other types of cancer [
32].
NR4A1 is part of a small subfamily of NHRs known as orphan receptors whose activating ligands are unknown.
NR4A1 has no known associations with endometrial cancer, though previous studies have identified roles for
NR4A1 in other cancers. Specifically, two reports have supported the role of
NR4A1 as a tumor suppressor in hematologic and breast cancer [
46,
47], while a third report proposed its role in potentiating TGF-β signaling and promoting metastasis in breast cancer [
48]
. In the present study, loss of
NR4A1 expression co-occurs with existing endometrial cancer subtypes, as we observed a positive relationship between
NR4A1 and
ESR1 expression (Fig.
7). Consistent with this observation, previous reports have observed the loss of
NR4A1 expression in triple-negative breast tumors, which lack expression of estrogen and progesterone receptors [
47].
Our results also identified
PPARG, a clinically-relevant NHR that encodes a protein known as peroxisome proliferator-activated receptor gamma (PPARG). PPARG is targeted by thiazolidinediones (TZDs), a class of agents used to treat type II diabetes. TZDs activate PPARG, whose natural ligands are free fatty acids, and also decrease insulin resistance [
49]. This association is of interest, as obese diabetic women are at a relative risk of six for developing endometrial cancer compared with non-obese, non-diabetic women [
50]. TZDs have been touted as potential anti-cancer agents, and differences in the expression of
PPARG within tumors could aid in the personalization of therapeutic regimens [
51]. The intersection between TZD administration,
PPARG expression, and endometrial cancer development deserves additional study.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.